Levin Capital Strategies’s Ocular Therapeutix OCUL Stock Holding History

Levin Capital Strategies’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,000	Closed	-$175K	–	247
2025 Q3	$175K	Buy	+15,000	New	+$179K	0.02%	199
2023 Q4	–	Sell	-22,500	Closed	-$70.7K	–	290
2023 Q3	$70.7K	Sell	22,500 -10,000	-31%	-$40.9K	0.01%	249
2023 Q2	$168K	Sell	32,500 -175,124	-84%	-$1.04M	0.02%	219
2023 Q1	$1.09M	Sell	207,624 -63,068	-23%	-$299K	0.14%	78
2022 Q4	$761K	Buy	270,692 +14,848	+6%	+$49.2K	0.1%	95
2022 Q3	$1.06M	Buy	255,844 +123,190	+93%	+$621K	0.14%	79
2022 Q2	$533K	Buy	+132,654	New	+$501K	0.06%	122
2020 Q3	–	Sell	-73,678	Closed	-$614K	–	283
2020 Q2	$614K	Buy	73,678 +43,678	+146%	+$290K	0.08%	95
2020 Q1	$148K	Sell	30,000 -15,000	-33%	-$74.1K	0.02%	141
2019 Q4	$178K	Buy	+45,000	New	+$156K	0.02%	188

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Levin Capital Strategies's OCUL Position: Q4 2025 in Review

Levin Capital Strategies sold out of Ocular Therapeutix (OCUL) in Q4 2025, closing a stake of 15,000 shares — an estimated $175K sold.

Levin Capital Strategies first reported a position in OCUL in Q4 2019 and held it in 10 quarters. The position peaked at $1.09M in Q1 2023. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

Levin Capital Strategies reported no remaining Ocular Therapeutix position as of Q4 2025 after selling out during the quarter.
Levin Capital Strategies sold 15,000 Ocular Therapeutix shares in Q4 2025, an estimated $175K.
Levin Capital Strategies first reported a position in Ocular Therapeutix in Q4 2019 and held it in 10 quarters.
Levin Capital Strategies's Ocular Therapeutix position peaked at $1.09M in Q1 2023.
249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on Levin Capital Strategies's 13F filing for Q4 2025, filed 30 Jan 2026.